Evidence map›Paper›PMID 33665572›Full record

ArticleiScience2021

Ancestral lysosomal enzymes with increased activity harbor therapeutic potential for treatment of Hunter syndrome.

Natalie M Hendrikse, Anna Sandegren, Tommy Andersson, Jenny Blomqvist, Åsa Makower, Dominik Possner, Chao Su, Niklas Thalén, Agneta Tjernberg, Ulrica Westermark and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Pseudo-perplexity in One Fell Swoop for Protein Fitness Estimation.bioRxiv : the preprint server for biology · 2024
    Article
  2. Article
  3. Article
  4. Data-driven enzyme engineering to identify function-enhancing enzymes.Protein engineering, design & selection : PEDS · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Natalie M HendrikseSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Anna SandegrenSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Tommy AnderssonSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Jenny BlomqvistSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Åsa MakowerSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Dominik PossnerSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Chao SuSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Niklas ThalénDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Agneta TjernbergSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Ulrica WestermarkSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Johan RockbergDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm 10691, Sweden.
Stefan Svensson GeliusSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Per-Olof SyrénScience for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna 171 21, Sweden.
Erik NordlingSwedish Orphan Biovitrum AB, Stockholm 112 76, Sweden.
Swedish Orphan Biovitrum (Sweden) · SEKTH Royal Institute of Technology · SEScience for Life Laboratory · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We show the successful application of ancestral sequence reconstruction to enhance the activity of iduronate-2-sulfatase (IDS), thereby increasing its therapeutic potential for the treatment of Hunter syndrome-a lysosomal storage disease caused by impaired function of IDS. Current treatment, enzyme replacement therapy with recombinant human IDS, does not alleviate all symptoms, and an unmet medical need remains. We reconstructed putative ancestral sequences of mammalian IDS and compared them with extant IDS. Some ancestral variants displayed up to 2-fold higher activity than human IDS in

Indexed as

BiochemistryStructural Biology

Identifiers

PMID33665572
PMCPMC7907806
OpenAlexW3099543027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.